Common blood pressure drug could make cancer therapy far more powerful

Researchers have discovered that telmisartan, a widely used blood pressure medication, can significantly enhance the effectiveness of olaparib, a cancer drug commonly used to treat BRCA-related tumors. The combination has demonstrated strong immune-boosting and anticancer effects in preclinical studies and is now undergoing human clinical trials. This breakthrough could expand olaparib's therapeutic benefits to cancer patients beyond those with BRCA mutations, potentially offering hope to a broader patient population. The findings suggest that repurposing existing medications may unlock new treatment strategies in oncology.